EGF Vesicles via Compressed Fluid Technology

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for preparing liposomes, such as traditional techniques, face challenges including the use of large solvents, high temperatures, and difficulties in controlling size and nanostructuring, leading to poor stability and reproducibility, especially when incorporating proteins like EGF.

Innovation Solution

The development of vesicles comprising EGF, a cationic surfactant, and cholesterol or its derivatives using compressed fluid technology, which involves preparing an aqueous solution of EGF and a cationic surfactant, dissolving cholesterol in an organic solvent expanded with a compressed fluid, and synthesizing vesicles by depressurization, resulting in highly stable and effective EGF delivery systems.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If traditional liposome preparation methods are used, then liposomes can be formed, but the process requires large amounts of solvents and high temperatures, leading to poor stability and reproducibility

Engineering Contradiction:

Improvestability and reproducibilityVSAvoidmanufacturing complexity

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The patent changes the physical and chemical parameters of the preparation process by using compressed fluids (supercritical or dense state) instead of traditional solvents. This parameter change eliminates the need for large amounts of solvents and high temperatures, directly improving stability and reproducibility while simplifying the manufacturing process. The compressed fluid technology allows for precise control of vesicle formation parameters.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent replaces the traditional mechanical and thermal processing methods with a compressed fluid-based system. Instead of using mechanical mixing, sonication, or high-temperature processing, the invention uses the unique properties of compressed fluids to spontaneously form vesicles, thereby improving reliability and reducing manufacturing complexity.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

2Manufacturing precision

If traditional liposome methods are used, then EGF can be incorporated, but the size and nanostructuring are difficult to control

Engineering Contradiction:

Improvesize control and nanostructuringVSAvoidprocess complexity

Core Design Contradiction:

Manufacturing precisionVSDevice complexity

Solution Approach 1:

The patent utilizes parameter changes in the compressed fluid system to precisely control vesicle size and nanostructuring. By adjusting pressure, temperature, and composition of the compressed fluid, the invention achieves precise control over the physical characteristics of the vesicles, including size distribution and structural uniformity, without requiring complex additional processing steps.

Inventive Principle:

Principle #35Parameter changes

3Reliability

If conventional EGF formulations are used, then EGF can be delivered, but the therapeutic efficacy is limited compared to vesicular systems

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidformulation complexity

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The patent creates a composite material system where EGF is integrated within vesicular structures formed by compressed fluid technology. This composite approach combines the therapeutic benefits of EGF with the protective and delivery-enhancing properties of the vesicle structure, significantly improving therapeutic efficacy. The formulation complexity is managed through the efficient compressed fluid preparation method.

Inventive Principle:

Principle #40Composite materials

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The EGF vesicles demonstrate enhanced therapeutic effectiveness, improved stability, and increased bioavailability, with yields of EGF incorporation approaching 100%, significantly surpassing previous methods, and exhibit antimicrobial and antifungal properties, making them suitable for treating complex wounds and tissue regeneration.

Implementation Method 1

dissolving cholesterol in an organic solvent expanded with a compressed fluid

Methodology Applied

Scientific EffectCompressed fluid expansion: Supercritical Fluid

Implementation Method 2

synthesizing vesicles by depressurization

Methodology Applied

Scientific EffectDepressurization: Depressurisation

Implementation Method 3

The vesicles are formed by depressurization of the expanded organic solution

Methodology Applied

Scientific EffectEvaporation: Evaporation

Data Source

PatentUS11510965B2Vesicles comprising epidermal growth factor and compositions thereof

Publication Date: 2022.11.29 CENT DE ING GENETICA & BIOTECNOLOGIA

AI summary

The invention relates to vesicles comprising Epidermal Growth Factor (EGF), a cationic surfactant and cholesterol or derivatives thereof. The invention also discloses a procedure for their preparation, based on compressed fluid technology (CFs). The vesicles of the invention are useful in the manufacture of drugs and cosmetics and in tissue engineering.